Enzyme study could unlock secrets of melanoma treatment resistance
NCT ID NCT04253080
First seen May 22, 2026 · Last updated Jun 06, 2026 · Updated 3 times
Summary
This study looked at a specific enzyme called IL4I1 in the blood and tissues of 127 people with cutaneous melanoma. Researchers wanted to see if this enzyme helps predict how fast the disease progresses and whether it plays a role in resistance to immunotherapy and targeted therapy. The goal is to better understand why some patients respond to treatment while others do not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology department
Paris, Île-de-France Region, 75014, France
Conditions
Explore the condition pages connected to this study.